Product Overview - The company's main quantitative products include those related to myocardial infarction, heart failure, inflammation assessment, and glycosylated hemoglobin [2] - The growth rate of qualitative products is relatively stable, with no significant increase expected in the near term [2] - New instruments and related quantitative products will be launched in the future, with details available in periodic reports [3] Future Planning - The three-year plan for quantitative products includes expanding the product line, planning for international product platforms, maintaining stable growth in quantitative products, and launching new quantitative products while expanding into overseas markets [3] - The company has research and reserves for raw materials, primarily focusing on biological raw materials [3] - There are currently no plans for external mergers and acquisitions [3] Market Insights - Sales of drug testing products are relatively stable, with future growth expected mainly in regions outside of Europe and the United States [3] - The primary sales channels for reproductive health products are supermarkets, e-commerce, and OTC channels [3] Research and Development - A laboratory was established in San Diego, USA, in 2015, staffed mainly by American-Chinese personnel, focusing on the development of new products and improvement of existing products [4]

Group 1: Company Goals and Strategy - The company aims to achieve a revenue target of 10 billion in 10 years, based on strategic planning conducted by professional institutions [2] - To reach this target, the company needs to achieve an annual growth rate of 30%-40%, which requires expanding beyond current POCT products into IVD and medical device products [2] Group 2: Financial Performance and Market Impact - The gross margin for pregnancy test strips is lower due to increased sales proportion, while the overall gross margin is affected by declining prices of domestic pregnancy products [3] - The depreciation of the RMB positively impacts the company as export sales significantly exceed the increased costs of imported raw materials [3] Group 3: Market Coverage and Client Distribution - The company has approximately 15% market share in tertiary hospitals, with a focus on ICU and emergency departments [3] - Coverage in grassroots hospitals is around 20%, indicating a significant market presence [4] Group 4: Product Development and Innovation - The company plans to enhance product sensitivity through optimization of biological raw materials and microfluidic technology [4] - New products are expected to be launched in the US market, including low-sensitivity drug tests and tumor marker detection products [4] Group 5: Sales Strategy and Market Positioning - The company employs a deep marketing strategy for quantitative products, while qualitative products are sold through provincial agents [5] - The company is focused on maintaining gross margins by continuously launching new products and optimizing production costs [5] Group 6: International Market Challenges - The company faced challenges in the Americas and Africa markets in 2015, attributed to a lack of new product launches and insufficient marketing personnel [5] - Future marketing efforts will concentrate on the US market, with plans to enhance bidding qualifications for better market penetration [5]

证券代码：万孚生物 证券简称：300482 编号： 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 投 资 者 关 系 活 动 | □ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □ 新闻发布会□路演活动 | | | □现场参观 | | | □ 其他（请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 中信建设证券、长城医药、和骞投资、广证恒生等。 | | 人员姓名 | | | 时间 | 2017-5-12 | | 地点 | 公司 | | 上 市 公 司 接 待 人 员姓名 | 董秘：陈斌 | | 投 资 者 关 系 活 动 | 介绍： ...

证券代码：万孚生物 证券简称：300482 编号：2020-001 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------------|----------------------------|-------|--------------------------------------------------------------------------| | | | | | | 投 资 者 关 系 活 动 | □ 特定对象调研 □分析师会议 | | | | 类别 | □ 媒体采访 □业绩说明会 | | | | | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | | | √其他 电话会议，投资者线上交流会 | | 参 与 单 位 名 称 及 | | | 海通证券、易方达基金管理有限公司、景顺长城基金管理有限公司、中国人 | | 人员姓名 | | | 保资产管理有限公司、光大保德信基金管理有限公司、前海开源基金管理有 | | | | | 限 公 司 、 富 国 基 金 管 理 有 限 公 司 ...

证券代码：万孚生物 证券简称：300482 编号： 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | |----------------------|---------------------------------------------------------------------| | | | | 投 资 者 关 系 活 动 | □ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □ 新闻发布会□路演活动 | | | □现场参观 | | | √ 其他 投资者交流会 | | 参 与 单 位 名 称 及 | 华泰瑞联、中信证券资管、广发基金、兴全基金、易方达基金、景顺长城基 | | 人员姓名 | 金、宝盈基金、安信证券、长江证券、国金证券、中信证券、华夏基金等 | | 时间 | 2019-09-10 | | 地点 | 公司及广州市天河区华观路 1961 号 | | 上 市 公 司 接 待 人 | 董事长王继华及公司核心经营管理团队。 | | 员姓名 | | | 投 资 者 关 系 活 动 | 1、Q: 行业未来是否会出现类似于现在心标、传染 ...

Group 1: Financial Performance and Market Insights - The gross margin for pregnancy products is relatively low, primarily due to changes in procurement patterns influenced by the economic crisis in Europe, where high-margin products are being replaced by lower-margin alternatives [2][3] - Domestic market growth is approximately over 50%, with significant contributions from clinical hospital markets, disease control tender markets, and OTC markets [4][5] - The company anticipates steady growth in pregnancy product sales due to the national two-child policy [3][4] Group 2: Product Development and Innovation - New products are expected to launch in December, including a blood gas testing system, with additional products in the pipeline for the following year [4][5] - The company is focusing on developing products for chronic diseases, including cardiovascular and respiratory diseases, indicating a significant growth potential in this area [5][6] - The introduction of microfluidic technology is expected to enhance product sensitivity and specificity, although it may increase costs [10][11] Group 3: Strategic Partnerships and Collaborations - The company is financially investing in AG Company and collaborating in market research, development, and manufacturing [3][4] - Plans to establish regional testing centers in collaboration with local health departments to integrate medical resources and improve service delivery [6][7] - The company is open to acquiring small overseas startups if suitable opportunities arise [5][6] Group 4: Market Strategy and Distribution Channels - The company does not exclusively target top-tier hospitals but allocates resources based on product characteristics and market acceptance in various hospital tiers [7][8] - The focus on channel mergers is shifting towards terminal aspects, with an emphasis on building regional testing centers to enhance service and sales [8][9] - The pharmacy channel is not a primary focus, with limited product offerings in this area, particularly for chronic disease products [10][11]

证券代码：万孚生物 证券简称：300482 编号： 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | |----------------------|--------------------------------------------------------------------------------| | | | | 投 资 者 关 系 活 动 | √ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □新闻发布会□路演活动 | | | □ 现场参观 | | | □其他（请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 长江证券、广发资管、兆丰禾投资、广州瑞民投资、源乘投资、农银汇理基 | | 人员姓名 | 金 | | 时间 | 2019-06-27 | | 地点 | 公司 | | 上 市 公 司 接 待 人 | 董事会秘书：胡洪 | | 员姓名 | | | 投 资 者 关 系 活 动 | 1 、 Q: 6 月 15 日开始在北京实施的北京医耗联动改革对的 POCT 行业及公 | | 主要内容介绍 | 司的影响有多大？ ...

证券代码：万孚生物 证券简称：300482 编号： 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | |----------------------|--------------------------------------------------------------------| | | | | 投 资 者 关 系 活 动 | √ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □新闻发布会□路演活动 | | | □ 现场参观 | | | □其他（请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 中信建投证券、金域投资、理成资产、东方阿尔法基金、华泰证券、宏道投 | | 人员姓名 | 资、中融基金、辰阳投资、合煦智远基金 | | 时间 | 2019-05-10 | | 地点 | 公司 | | 上 市 公 司 接 待 人 | 董事长：王继华，董事会秘书：胡洪 | | 员姓名 | | | 投 资 者 关 系 活 动 | 1、Q: 请介绍一下心标市场情况和行业竞争情况。 | | 主要内容介绍 | A: 在北京、上海等一线城市三 ...

证券代码：万孚生物 证券简称：300482 编号： 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | |----------------------|--------------------------------------------------------------------------| | | | | 投 资 者 关 系 活 动 | □ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □ 新闻发布会□路演活动 | | | □现场参观 | | | □ 其他（请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 阿巴马资产、茗晖基金、浦银安盛、银华基金。 | | 人员姓名 | | | 时间 | 2018-5-4 | | 地点 | 公司 | | 上 市 公 司 接 待 人 | 财务总监：余芳霞、证代：华俊 | | 员姓名 | | | 投 资 者 关 系 活 动 | 1 、Q：一季度分产品、分区域的收入情况？公司研发费用的主要研发方 | | 主要内容介绍 | 向？ | | | A ： 2018 年一季度公司收入情况为：传染病检 ...

证券代码：万孚生物 证券简称：300482 编号： 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | |----------------------|-------------------------------------------------------------------------| | | | | 投 资 者 关 系 活 动 | □ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □ 新闻发布会□路演活动 | | | □现场参观 | | | □ 其他（请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 国联证券、中国人寿养老保险、广发证券、方正证券、国寿安保、上海磐 | | 人员姓名 | 耀、南土资管、广汇鑫资管、百创汇国际、第一创业、渤海证券、牛行资 | | | 兴证券。 | | | 管、永赢基金、百年保险、六禾投资、安信证券、中信建投、华泰证券、东 | | 时间 | 2018-5-15 | | 地点 | 公司 | | 上 市 公 司 接 待 人 | 财务总监：余芳霞，证券事务代表：华俊 | | 员姓名 | | ...